Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma … Read more
Celltrion Inc - Asset Resilience Ratio
Celltrion Inc (068270) has an Asset Resilience Ratio of 0.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Celltrion Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Celltrion Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩143.62 Billion | 0.68% |
| Total Liquid Assets | ₩143.62 Billion | 0.68% |
Asset Resilience Insights
- Limited Liquidity: Celltrion Inc maintains only 0.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Celltrion Inc Industry Peers by Asset Resilience Ratio
Compare Celltrion Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
CohBar Inc
NASDAQ:CWBR |
Biotechnology | 48.93% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
Annual Asset Resilience Ratio for Celltrion Inc (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Celltrion Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.70% | ₩146.61 Billion | ₩21.06 Trillion | -0.27pp |
| 2023-12-31 | 0.97% | ₩192.89 Billion | ₩19.92 Trillion | +0.23pp |
| 2022-12-31 | 0.73% | ₩43.28 Billion | ₩5.89 Trillion | +0.18pp |
| 2021-12-31 | 0.56% | ₩31.57 Billion | ₩5.67 Trillion | +0.28pp |
| 2020-12-31 | 0.28% | ₩14.03 Billion | ₩5.02 Trillion | -1.84pp |
| 2019-12-31 | 2.12% | ₩81.68 Billion | ₩3.86 Trillion | -1.36pp |
| 2018-12-31 | 3.47% | ₩121.64 Billion | ₩3.50 Trillion | -0.74pp |
| 2017-12-31 | 4.21% | ₩138.72 Billion | ₩3.29 Trillion | +4.02pp |
| 2016-12-31 | 0.19% | ₩5.77 Billion | ₩3.02 Trillion | -0.03pp |
| 2015-12-31 | 0.22% | ₩6.00 Billion | ₩2.75 Trillion | -1.08pp |
| 2014-12-31 | 1.30% | ₩30.15 Billion | ₩2.32 Trillion | -0.34pp |
| 2013-12-31 | 1.64% | ₩32.38 Billion | ₩1.98 Trillion | -1.25pp |
| 2012-12-31 | 2.89% | ₩50.01 Billion | ₩1.73 Trillion | +2.22pp |
| 2011-12-31 | 0.66% | ₩9.36 Billion | ₩1.41 Trillion | -7.45pp |
| 2010-12-31 | 8.12% | ₩93.81 Billion | ₩1.16 Trillion | +7.07pp |
| 2009-12-31 | 1.05% | ₩5.88 Billion | ₩559.20 Billion | +0.27pp |
| 2008-12-31 | 0.78% | ₩3.89 Billion | ₩499.26 Billion | -3.48pp |
| 2007-12-31 | 4.25% | ₩2.62 Billion | ₩61.46 Billion | -- |